Returns for the 36 biopharma firms that went public in the first half of 2018 – including 14 in June alone – averaged 20.9%, stabilizing after a dip earlier in the year. But while drug developer returns have been on a rollercoaster ride, they're doing better than broader stock indices.
Biopharmaceutical companies that launched initial public offerings in the US during the first half of 2018 posted an average return of 20.9% as of July 3, stabilizing after the valuation rollercoaster sped to a major peak then fell to a much lower return earlier this year.
But the IPO class of 2018 still is performing better than broader stock indices – even with almost half of...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
